Andreas Harstrick, MD

Articles by Andreas Harstrick, MD

Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer

ByUte Klaassen, MD,David Borquez, MD,Stephanie Lang, MD,Carsten Oberhoff, MD,Andreas Harstrick, MD,Siegfried Seeber, MD, PhD,Steven Benner, MD

July 1st 1999

This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral

Latest Updated Articles

Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer
Published: July 1st 1999 | Updated:

Andreas Harstrick, MD

Articles by Andreas Harstrick, MD

Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

Durvalumab/FLOT Cemented as New SOC in Gastric/GEJ Cancers

Why is Lymphedema Detected So Late in Breast Cancer?

The Evolution of Distress Screening in Cancer Care

A Look Back on the Top 10 Oncology Interviews in 2025